VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
VACCINEX, INC.
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $3.22M
- P/E (TTM)
- –
- Dividend yield
- –
Vaccinex statistics
Financials through Dec 31, 2024, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Vaccinex | Industry median |
|---|---|---|
| Market Cap | $2.68M | $164.85M |
| Enterprise Value | $1.59M | $87.06M |
| PS Ratio | 4.45 | 3.60 |
Enterprise value
| Measure | Vaccinex | Industry median |
|---|---|---|
| EV / Sales | 2.65 | 2.43 |
Income (trailing twelve months)
| Measure | Vaccinex | Industry median |
|---|---|---|
| Revenue | $601.00K | $57.94M |
| Operating Income | -$18.74M | -$21.44M |
| Pretax Income | -$18.63M | -$14.45M |
| Net Income | -$18.63M | -$22.46M |
| EBITDA | -$18.74M | -$16.91M |
| EPS (Diluted) | -$8.88 | -$0.83 |
Margins
| Measure | Vaccinex | Industry median |
|---|---|---|
| Operating Margin | -3117.3% | -44.5% |
| Pretax Margin | -3100.5% | -13.0% |
| Profit Margin | -3100.5% | -39.2% |
| EBITDA Margin | -3117.3% | -31.3% |
| FCF Margin | -2696.8% | -8.85% |
Returns
| Measure | Vaccinex | Industry median |
|---|---|---|
| Return on Assets (ROA) | -717.8% | -41.0% |
Growth
| Measure | Vaccinex | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -12.6% | 2.25% |
| Revenue Growth (5Y CAGR) | 2.82% | 6.42% |
Balance sheet
| Measure | Vaccinex | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.11M | $62.42M |
| Total Debt | $25.00K | $120.13M |
| Net Cash (Debt) | $1.08M | $15.68M |
| Net Cash Per Share | $0.40 | $0.66 |
| Working Capital | -$2.55M | $75.77M |
Financial position
| Measure | Vaccinex | Industry median |
|---|---|---|
| Current Ratio | 0.50 | 3.30 |
| Quick Ratio | 0.38 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Vaccinex | Industry median |
|---|---|---|
| Operating Cash Flow | -$16.19M | -$12.35M |
| Capital Expenditures | -$22.00K | -$1.06M |
| Free Cash Flow | -$16.21M | -$20.28M |
| FCF Per Share | -$6.06 | -$0.42 |
Efficiency
| Measure | Vaccinex | Industry median |
|---|---|---|
| Asset Turnover | 0.23 | 0.38 |
| Revenue Per Employee | $26.13K | $398.96K |
| Profits Per Employee | -$810.17K | -$703.34K |
| Employee Count | 23 | 74 |
Dividends and yields
| Measure | Vaccinex | Industry median |
|---|---|---|
| Earnings Yield | -696.2% | -22.7% |
| FCF Yield | -605.5% | -9.07% |
Shares
| Measure | Vaccinex | Industry median |
|---|---|---|
| Shares Outstanding | 2,676,640 | 58,179,650 |
| Shares Change (QoQ) | 2.96% | 0.54% |
| Float | 334,371 | 49,173,100 |
| Shares Held by Insiders | 87.5% | 11.6% |
Taxes
| Measure | Vaccinex | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Vaccinex | Industry median |
|---|---|---|
| Altman Z-Score | -217.82 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Vaccinex's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.